Platinum Investment Management’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Platinum Investment Management’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-231,521	Closed	-$24.8M	–	161
2023 Q1	$24.8M	Sell	231,521 -34,270	-13%	-$3.94M	0.86%	27
2022 Q4	$29.2M	Sell	265,791 -87,565	-25%	-$5.68M	1.11%	21
2022 Q3	$20.9M	Sell	353,356 -78,211	-18%	-$3.58M	0.87%	27
2022 Q2	$12.2M	Hold	431,567	–	–	0.46%	35
2022 Q1	$16.3M	Sell	431,567 -89,962	-17%	-$3.56M	0.5%	34
2021 Q4	$20.6M	Buy	521,529 +19,009	+4%	+$595K	0.57%	34
2021 Q3	$11.9M	Buy	502,520 +147,619	+42%	+$3.48M	0.34%	42
2021 Q2	$8.72M	Buy	354,901 +213,753	+151%	+$4.77M	0.2%	48
2021 Q1	$2.58M	Buy	+141,148	New	+$2.91M	0.06%	78

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Platinum Investment Management's RXDX Position: Q2 2023 in Review

Platinum Investment Management sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 231,521 shares — an estimated $24.8M sold.

Platinum Investment Management first reported a position in RXDX in Q1 2021 and held it in 9 quarters. The position peaked at $29.2M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Platinum Investment Management reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Platinum Investment Management sold 231,521 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $24.8M.
Platinum Investment Management first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
Platinum Investment Management's Prometheus Biosciences, Inc. Common Stock position peaked at $29.2M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Platinum Investment Management's 13F filing for Q2 2023, filed 11 Aug 2023.